Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (3)
Type
Type
Guidance (84)
Quality standard (3)
Guidance programme
Guidance programme
HealthTech guidance (8)
Technology appraisal guidance (76)
Apply filters
Showing 1 to 87 of 87
Keyword or reference number: in
`Remove $Keyword or reference number: in filter`
Guidance and quality standards awaiting development
Title
Type
Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa
in
people of any age [ID6746]
Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum
in
people 2 years and over [ID6252]
Technology appraisal guidance
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant
in
people 12 years and over [ID6664]
Technology appraisal guidance
Amlitelimab for treating moderate to severe atopic dermatitis
in
people 12 years and over [TSID12394]
Technology appraisal guidance
Artificial intelligence (AI) technologies to help detect fractures on X-rays
in
urgent care
HealthTech guidance
Artificial intelligence (AI)-derived software to help clinical decision making
in
stroke
HealthTech guidance
Baloxavir marboxil for treating influenza
in
people at high risk of complications [ID3794]
Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia
in
people with breast cancer [TSID11769]
Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome
in
people 12 years and over [ID6322]
Technology appraisal guidance
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis
in
people 2 years and over [ID6486]
Technology appraisal guidance
Carfilzomib
in
combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]
Technology appraisal guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures
in
epilepsy [TSID10214]
Technology appraisal guidance
CM-AT for behaviours associated with autism
in
children and young people [ID6731]
Technology appraisal guidance
Concizumab for treating severe haemophilia A or moderate to severe haemophilia B
in
people 12 years and over without inhibitors [ID5099]
Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma
in
people aged 12 and over [TSID11838]
Technology appraisal guidance
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy
in
children 4 to 7 years [ID3897]
Technology appraisal guidance
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events
in
bone malignancies [TSID12150]
Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria
in
people 12 years and over [ID6160]
Technology appraisal guidance
Donanemab for reducing the risk of mild cognitive impairment
in
preclinical Alzheimer's disease [ID6675]
Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency
in
people of any age who had symptoms before 13 years [ID6484]
Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis
in
children 1 to 11 years [ID6492]
Technology appraisal guidance
Durvalumab
in
combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]
Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours
in
people previously untreated with BCG [ID5080]
Technology appraisal guidance
Encaleret for treating autosomal dominant hypocalcaemia type 1
in
people 16 years and over [TSID12390]
Technology appraisal guidance
Enlicitide decanoate for treating hyperlipidaemia
in
people at risk of an atherosclerotic cardiovascular disease event [ID6656]
Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause
in
people aged 40 to 65 [ID4037]
Technology appraisal guidance
Etavopivat for treating sickle cell disease
in
people 12 years and over [ID6698]
Technology appraisal guidance
Fenfluramine for treating seizures caused by CDKL5 deficiency disorder
in
people 1 year and over [ID6740]
Technology appraisal guidance
Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss
in
babies
HealthTech guidance
Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen
in
people 5 years and over [TSID12379]
Technology appraisal guidance
Heart valve disease
in
adults
Quality standard
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol
in
people 12 to 17 years [TSID12129]
Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis
in
people 12 years and over having an angiotensin II receptor blocker [ID6469]
Technology appraisal guidance
Isatuximab
in
combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]
Technology appraisal guidance
Isatuximab
in
combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]
Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations
in
Parkinson's disease [ID3868]
Technology appraisal guidance
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis
in
people 2 to 17 years [ID6590]
Technology appraisal guidance
KardiaMobile 6L for measuring cardiac QT interval
in
adults having antipsychotic medication
HealthTech guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma
in
people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma
in
adults [TSID10652]
Technology appraisal guidance
Linerixibat for treating pruritus
in
people with primary biliary cholangitis [ID6265]
Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia
in
people aged 1 to 21 years [ID4017]
Technology appraisal guidance
Lonapegsomatropin for treating growth hormone deficiency
in
people 3 to 17 years [TSID12395]
Technology appraisal guidance
Luspatercept for treating anaemia
in
non-transfusion dependent beta-thalassaemia [ID3870]
Technology appraisal guidance
Marstacimab for treating severe haemophilia A or B
in
people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]
Technology appraisal guidance
Navepegritide for treating achondroplasia
in
people 2 to 15 years [ID6538]
Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1
in
people 6 years and over [TSID11777]
Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis
in
people 2 to 17 yearslimab for Myasthenia gravis [TSID12382]
Technology appraisal guidance
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome
in
people 2 years and over [ID6692]
Technology appraisal guidance
OCU400 for treating retinitis pigmentosa
in
people 5 years and over [PDID6687]
Technology appraisal guidance
Odevixibat for treating biliary atresia
in
children following Kasai hepatoportoenterostomy [ID6627]
Technology appraisal guidance
Olomorasib
in
combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [TSID12376]
Technology appraisal guidance
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a
in
people 8 years and over [TSID11865]
Technology appraisal guidance
Pelacarsen for reducing the risk of cardiovascular events
in
people with established cardiovascular disease and high lipoprotein (a) [ID6559]
Technology appraisal guidance
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures
in
children aged below 12 years with epilepsy [ID1587]
Technology appraisal guidance
Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support
in
high-risk percutaneous coronary interventions
HealthTech guidance
PLX-PAD for treating muscle injury after arthroplasty for hip fracture
in
people 60 to 90 years [ID3989]
Technology appraisal guidance
Point-of-care lipid tests for cardiovascular disease prevention
in
primary and community care
HealthTech guidance
Procalcitonin to guide decisions on stopping antibiotics
in
people with confirmed or highly suspected sepsis
HealthTech guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A
in
people aged 16 and over [ID1439]
Technology appraisal guidance
Ravulizumab for preventing kidney events
in
people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]
Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant
in
people aged 28 days and over [TSID10642][ID6319]
Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines
in
people 12 to 17 years [ID6649]
Technology appraisal guidance
Ritlecitinib for treating non-segmental vitiligo
in
people 12 years and over [ID6584]
Technology appraisal guidance
Rusfertide for treating polycythaemia vera
in
people having phlebotomy [ID6709]
Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant
in
people 28 days to 17 years [ID6410]
Technology appraisal guidance
Safeguarding adults
in
care homes
Quality standard
Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines
in
people who have not had pomalidomide [ID6705]
Technology appraisal guidance
Selinexor with ruxolitinib for treating splenomegaly or symptoms
in
myelofibrosis untreated with a JAK inhibitor [ID6717]
Technology appraisal guidance
Semaglutide for managing overweight and obesity
in
children 6 to 11 years [TSID12381]
Technology appraisal guidance
Sepiapterin for treating hyperphenylalaninaemia
in
phenylketonuria
in
people of any age [ID6750]
Technology appraisal guidance
Somapacitan for treating growth failure caused by Turner syndrome
in
people 2 to 17 years [ID6621]
Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis
in
people 8 years and over [ID3955]
Technology appraisal guidance
Supporting independent living and preventing isolation
in
adults of working age with social care needs
Quality standard
Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment
in
people 12 years and over [ID6630]
Technology appraisal guidance
Sutimlimab for treating haemolytic anaemia
in
people with cold agglutinin disease [ID6673]
Technology appraisal guidance
Tirzepatide for managing overweight and obesity
in
people 12 to 17 years [ID6707]
Technology appraisal guidance
Tirzepatide for reducing the risk of major adverse cardiovascular events
in
people with type 2 diabetes and cardiovascular disease [ID6733]
Technology appraisal guidance
Tirzepatide for treating type 2 diabetes
in
people 10 to 17 years [ID6539]
Technology appraisal guidance
Tislelizumab
in
combination for untreated advanced non-small-cell lung cancer [ID6708]
Technology appraisal guidance
Topical tapinarof for treating atopic dermatitis
in
people 2 years and over [ID6713]
Technology appraisal guidance
Upadacitinib for treating moderate to severe hidradenitis suppurativa
in
people 12 years and over [ID6666]
Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease
in
people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]
Technology appraisal guidance
Vertebral body tethering for idiopathic scoliosis
in
children and young people
HealthTech guidance
Vosoritide for treating achondroplasia
in
children and young people under 18 years [ID3807]
Technology appraisal guidance
WP1048 for treating grass pollen allergy
in
people aged 18 to 60 [TSID10467]
Technology appraisal guidance
Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva
in
people 12 years and over [ID6637]
Technology appraisal guidance
Zimislecel for treating type 1 diabetes
in
people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]
Technology appraisal guidance
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top